| Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial C Bachert, JK Han, MY Desrosiers, P Gevaert, E Heffler, C Hopkins, ... Journal of Allergy and Clinical Immunology 149 (4), 1309-1317. e12, 2022 | 331 | 2022 |
| Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis ME Wechsler, P Nair, B Terrier, B Walz, A Bourdin, DRW Jayne, ... New England Journal of Medicine 390 (10), 911-921, 2024 | 187 | 2024 |
| A phase 2a, double-blind, placebo-controlled randomized trial of inhaled TLR9 agonist AZD1419 in asthma I Psallidas, V Backer, P Kuna, R Palmér, S Necander, M Aurell, ... American Journal of Respiratory and Critical Care Medicine 203 (3), 296-306, 2021 | 29 | 2021 |
| The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD D Singh, J Beier, C Astbury, MG Belvisi, CA Da Silva, A Jauhiainen, ... European Respiratory Journal 59 (4), 2022 | 17 | 2022 |
| Characterisation of pharmacokinetics, safety and tolerability in a first‐in‐human study for AZD8154, a novel inhaled selective PI3Kγδ dual inhibitor targeting airway … MW Sadiq, S Asimus, MG Belvisi, W Brailsford, R Fransson, R Fuhr, ... British Journal of Clinical Pharmacology 88 (1), 260-270, 2022 | 16 | 2022 |
| Physical activity end-points in trials of chronic respiratory diseases: summary of evidence C Rist, N Karlsson, S Necander, CA Da Silva ERJ Open Research 8 (1), 2022 | 11 | 2022 |
| Characterization of clinical absorption, distribution, metabolism, and excretion and pharmacokinetics of velsecorat using an intravenous microtracer combined with an inhaled … AA Holmberg, L Weidolf, S Necander, P Bold, S Sidhu, M Pelay-Gimeno, ... Drug Metabolism and Disposition 50 (2), 150-157, 2022 | 7 | 2022 |
| Results of a phase 2b dose finding study of velsecorat, an inhaled non-steroidal, selective Glucocorticoid Receptor Modulator in Asthma (GRANIT) GL Chupp, KM Beeh, A Jauhiainen, S Necander, MN Brown, ... D7. D007 ADVANCES IN ASTHMA THERAPIES, A1202-A1202, 2021 | 5 | 2021 |
| Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis PA Merkel, PK Nair, N Khalidi, B Terrier, B Hellmich, A Bourdin, ... Annals of the rheumatic diseases, 2025 | 4 | 2025 |
| Efficacy and safety of benralizumab compared with mepolizumab in the treatment of eosinophilic granulomatosis with polyangiitis in patients receiving standard of care therapy … M Wechsler, P Nair, B Terrier, B Walz, A Bourdin, D Jayne, D Jackson, ... ARTHRITIS & RHEUMATOLOGY 75, 5222-5225, 2023 | 4 | 2023 |
| Asthma remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) following treatment with benralizumab or mepolizumab A Bourdin, ME Wechsler, DJ Jackson, S Siddiqui, P Baudy, ... European Respiratory Journal 64 (suppl 68), 2024 | 2 | 2024 |
| POS0858 HOW SYMPTOMS AND TREATMENTS IMPACT THE EXPERIENCES OF PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS PARTICIPATING IN A CLINICAL TRIAL PA Merkel, B Hellmich, C Pagnoux, U Specks, M Wechsler, VH Shih, ... Annals of the Rheumatic Diseases 83, 1071-1072, 2024 | 2 | 2024 |
| POS0862 the Efficacy of Eosinophil-Targeting Therapies According to Anca Status in Patients with Eosinophilic Granulomatosis with Polyangiitis: A Post-Hoc Analysis of the Phase … B Terrier, DRW Jayne, B Hellmich, PA Merkel, N Agmon-Levin, P Nair, ... Annals of the Rheumatic Diseases 83, 1118-1120, 2024 | 2 | 2024 |
| OP0188 EFFECT OF BENRALIZUMAB VERSUS MEPOLIZUMAB ON REDUCTION IN ORAL GLUCOCORTICOID USE IN PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS B Hellmich, M Wechsler, PA Merkel, P Nair, A Bourdin, DRW Jayne, ... Annals of the Rheumatic Diseases 83, 186-187, 2024 | 2 | 2024 |
| Two-year Efficacy and Safety of Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis ME Wechsler, P Nair, N Khalidi, B Terrier, B Hellmich, A Bourdin, ... American Journal of Respiratory and Critical Care Medicine 211 (Abstracts …, 2025 | 1 | 2025 |
| Efficacy of benralizumab and mepolizumab on asthma outcomes in patients with eosinophilic granulomatosis with polyangiitis M Wechsler, A Bourdin, P Chanez, D Jackson, S Siddiqui, U Specks, ... Annals of Allergy, Asthma & Immunology 133 (6), S49-S50, 2024 | 1 | 2024 |
| Complete remission in Eosinophilic Granulomatosis with Polyangiitis (EGPA) in the MANDARA TRIAL of Benralizumab vs Mepolizumab ME Wechsler, N Agmon-Levin, DRW Jayne, C Pagnoux, U Specks, ... SWISS MEDICAL WEEKLY 154, 5S-5S, 2024 | 1 | 2024 |
| Characteristics of Relapses in Patients with Eosinophilic Granulomatosis with Polyangiitis P Merkel, D Jayne, U Specks, C Pagnoux, P Nair, N Khalidi, A Bourdin, ... ARTHRITIS & RHEUMATOLOGY 76, 3282-3284, 2024 | 1 | 2024 |
| Late Breaking Abstract-Benralizumab reduces eosinophils and ANCA in sputum in EGPA M Mukherjee, NS Tan, C Huang, B Kim, K Radford, CV Garrido, A Bhalla, ... European Respiratory Journal 64 (suppl 68), 2024 | 1 | 2024 |
| Effect of treatment with benralizumab or mepolizumab on the serum proteome in eosinophilic granulomatosis with polyangiitis E Rodriguez-Suarez, M Cardner, ME Wechsler, PA Merkel, B Terrier, ... European Respiratory Journal 64 (suppl 68), 2024 | 1 | 2024 |
